629 related articles for article (PubMed ID: 1691760)
1. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
3. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
4. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
Davé SJ; Sodetz JM
J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
[TBL] [Abstract][Full Text] [Related]
6. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
7. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
8. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
9. Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane.
Blaas P; Berger B; Weber S; Peter HH; Hänsch GM
J Immunol; 1988 May; 140(9):3045-51. PubMed ID: 3361126
[TBL] [Abstract][Full Text] [Related]
10. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.
Hänsch GM; Schönermark S; Roelcke D
J Clin Invest; 1987 Jul; 80(1):7-12. PubMed ID: 3597779
[TBL] [Abstract][Full Text] [Related]
11. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
Bhakdi S; Tranum-Jensen J
J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
[TBL] [Abstract][Full Text] [Related]
12. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
Kochi SK; Johnson RC; Dalmasso AP
J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.
Podack ER; Preissner KT; Müller-Eberhard HJ
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():89-96. PubMed ID: 6587746
[TBL] [Abstract][Full Text] [Related]
14. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
15. Isolation of erythrocyte membrane inhibitor of reactive lysis type II. Identification as glycophorin A.
Tomita A; Radike EL; Parker CJ
J Immunol; 1993 Sep; 151(6):3308-23. PubMed ID: 7690802
[TBL] [Abstract][Full Text] [Related]
16. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
Kontermann R; Deppisch R; Rauterberg EW
Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
[TBL] [Abstract][Full Text] [Related]
17. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
18. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
Hammer CH; Shin ML; Abramovitz AS; Mayer MM
J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
[TBL] [Abstract][Full Text] [Related]
19. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement.
Whitlow MB; Iida K; Stefanova I; Bernard A; Nussenzweig V
Cell Immunol; 1990 Mar; 126(1):176-84. PubMed ID: 1689219
[TBL] [Abstract][Full Text] [Related]
20. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
